# Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

> **NCT05846373** · PHASE2 · COMPLETED · sponsor: **Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh** · enrollment: 58 (actual)

## Conditions studied

- Migraine Prophylaxis

## Interventions

- **DRUG:** Nicotinic Acid 500 MG Extended Release Oral Tablet
- **DRUG:** Nicotinic Acid 1000 MG Extended Release Oral Tablet
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05846373
- **Lead sponsor:** Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-25
- **Primary completion:** 2024-01-10
- **Final completion:** 2024-01-10
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05846373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05846373, "Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05846373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*